Mirum Pharmaceuticals, Inc. 8-K

What Happened

• On May 6, 2026, Mirum Pharmaceuticals, Inc. announced a corporate update and its financial results for the quarter ended March 31, 2026 via a press release. The press release is furnished as Exhibit 99.1 to a Current Report on Form 8-K under Item 2.02 (Results of Operations and Financial Condition). The Form 8-K notes the furnished information is not deemed “filed” under Section 18 of the Exchange Act. The filing is signed by CEO Christopher Peetz.

Key Details

• Press release dated May 6, 2026 relating to the quarter ended March 31, 2026.
• Information furnished under Item 2.02 (Results of Operations and Financial Condition).
• Press release included as Exhibit 99.1 to the Form 8-K.
• Filing signed by Christopher Peetz, Chief Executive Officer.

Why It Matters

• The press release contains the company’s reported quarterly results (earnings, revenue and related updates) and is the first source for investors to review Mirum’s latest financial performance and corporate guidance.
• Because the information was furnished rather than “filed,” it is expressly stated not to be subject to certain Exchange Act liabilities; investors should read the press release and other SEC filings for full, actionable financial details.